Search alternatives:
point decrease » point increase (Expand Search)
2 decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
2 decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
181
-
182
Decrease of galectin-3 positive cells in bleomycin-injured lung tissue upon administration of hUC-MSC.
Published 2018“…Lung sections obtained from C57BL/6 mice (n = 8 per group) were immunostained with anti-galectin-3 antibody. At each time point, the number of immunoreactive macrophages infiltrating the lungs are significantly decreased by hUC-MSC infusion in comparison to bleomycin-treated mice. …”
-
183
-
184
Flow diagram of the study.
Published 2023“…A total of 162 patients were included. The SOFA score on POD 5 was significantly higher in the High-decrease group compared with the Low-decrease group (5.2 ± 2.6 vs. 4.1 ± 2.3; mean difference: 1.1, 95% CI: 0.3 to 1.8; P = 0.005). …”
-
185
Baseline characteristics of patients.
Published 2023“…A total of 162 patients were included. The SOFA score on POD 5 was significantly higher in the High-decrease group compared with the Low-decrease group (5.2 ± 2.6 vs. 4.1 ± 2.3; mean difference: 1.1, 95% CI: 0.3 to 1.8; P = 0.005). …”
-
186
Increases in 1,5-anhydrosorbitol and decreases in ascorbic acid following RYGB.
Published 2013“…B) For ascorbic acid, the ANOVA model did not detect group-specific changes over time (no group:time interaction), but indicated significant decreases from T0 to T6 in both groups. Overall, 1,5-anhydrosorbitol and ascorbic acid were significantly different at each time point between OB and OB/D subgroups (p<0.01, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0007905#pone-0007905-t002" target="_blank"><b>TABLE 2</b></a>).…”
-
187
-
188
-
189
HRMECs treated with SUZ12 siRNA demonstrate increased miR-200b expression, decreased VEGF expression and decreased endothelial branching.
Published 2015“…However, transfection of SUZ12 siRNA significantly reduced endothelial branching compared to HG+control siRNA. [NG+control siRNA = 5mM D-glucose + 100nM control siRNA, HG+control siRNA = 25mM D-glucose + 100nM control siRNA, HG+EZH2 siRNA = 25mM D-glucose + 100nM EZH2 siRNA, HG+SUZ12 siRNA = 25mM + 100nM SUZ12 siRNA; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to U6 or β-actin and expressed as a fold change of NG+control siRNA].…”
-
190
-
191
-
192
A homozygous point mutation in the <i>Mrps34</i> gene causes a decrease in the MRPS34 protein.
Published 2015“…The 5′- and 3′-untranslated regions are shown as grey boxes and the predicted mitochondrial targeting sequence is shown as a black box (predicted using MitoProtII, [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1005089#pgen.1005089.ref040" target="_blank">40</a>]). …”
-
193
-
194
Inhibition of GLS1 decreases the proportion of CCR6 and CXCR3 expressing CD4<sup>+</sup> T cells.
Published 2016“…BPTES and 968 significantly decrease the proportion of CCR6 expressing cells under normoxia both at day 3 and 5, whereas 968 but not BPTES decrease the proportion of CCR6 expressing cells under hypoxia both at day 3 and 5. …”
-
195
-
196
-
197
-
198
-
199
ApoER2 expression increases Aβ production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of γ-secretase activity-5
Published 2011“…<p><b>Copyright information:</b></p><p>Taken from "ApoER2 expression increases Aβ production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of γ-secretase activity"</p><p>http://www.molecularneurodegeneration.com/content/2/1/14</p><p>Molecular Neurodegeneration 2007;2():14-14.…”
-
200